Jump to Header Jump to Main Content Jump to Footer

A Phase II Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Jeremy Phillip Harris


A Study On:

  • Soft Tissue

Status:

  • Open

Eligibility

Adults

Interested in joining this trial?

Official Title

A Phase II Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Details

This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.


Eligibility

You can join if...

Inclusion Criteria

  1. Newly diagnosed and a histopathologically potentially resectable soft tissue sarcoma of the extremity or trunk of the following subtypes:
    • Cohort 1: liposarcoma (excluding myxoid liposarcoma)
    • Cohort 2: leiomyosarcoma
    • Cohort 3: undifferentiated pleomorphic sarcoma (UPS)/ malignant fibrous histiosarcoma (MFH)
  2. Willingness to provide mandatory blood and tissue samples for correlative studies and central pathology confirmation of surgical specimens collected during study participation
  3. Willingness to provide a tissue sample that is mandatory at the time of surgery (if applicable) and the determination of the primary objective of the study

Exclusion Criteria

  1. Patients must have had no prior radiotherapy to tumor-involved sites
  2. Previous treatment with talimogene laherparepvec (T-VEC) or any other oncolytic virus
  3. Patients with metastatic disease

Get in touch with our study team